CompletedNot Applicable

Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.

France9 participantsStarted 2022-02-16

Plain-language summary

Antimicrobial resistance is a major threat worldwide and now concerns last-ressource antibiotics such as carbapenems. As the resistance to carbapenems is directly due to their use, their spare has become a public health emergency. Their efficacy in ventilator-associated pneumonia has never been compared to other classes of antibiotics such as piperacillin-tazobactam which can be an alternative to carbapenems.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient above 18 year-old admitted to intensive care unit * ESBL-E fecal carriage according to current screening recommendations * Suspicion of ventilator-associated pneumonia according to ICU society guidelines Exclusion Criteria: * Septic shock according to Sepsis-3 classification * Neutropenia (neutrophils count \< 500/mm3) * Known fecal carriage of Carbapenemase-producing Enterobacteriaceae or multi-drug resistant A. baumanii during the past 6 months. * Infection with a bacteria resistant to piperacillin-tazobactam during the past 6 months * Treatment with piperacillin-tazobactam in the 10 previous days * Proven hypersensitivity to penicillin or tazobactam * Pregnancy or breastfeeding * Curatorship or guardianship * Prisoners * No health insurance

What they're measuring

Mortality in Intensive Care Unit (ICU)

Timeframe: at day 28 after inclusion

Trial details

NCT IDNCT04276480

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-04-22

View on ClinicalTrials.gov More Enterobacteriaceae Infections trials